NDC 59417-117 – Vyvanse
Lisdexamfetamine Dimesylate 30 mg/1 · Tablet, Chewable · Oral
Product NDC59417-117
Product details
- Brand name
- Vyvanse
- Generic name
- Lisdexamfetamine Dimesylate
- Labeler
- Takeda Pharmaceuticals America, Inc.
- Dosage form
- Tablet, Chewable
- Route
- Oral
- Marketing category
- NDA · NDA208510
- Marketed since
- January 28, 2017
- Listing expires
- December 31, 2027
- Pharmacologic class
- Central Nervous System Stimulant
Active ingredients
- Lisdexamfetamine Dimesylate 30 mg/1
Package NDC codes (1)
| Package NDC | Description | Since |
|---|---|---|
| 59417-117-01 | 100 TABLET, CHEWABLE in 1 BOTTLE (59417-117-01) | Jan 28, 2017 |
Recalls mentioning this NDC
- D-0006-2017 Oct 12, 2016 · Class III
Presence of Foreign Tablets/Capsules
Other Vyvanse products
- 59417-115 Lisdexamfetamine Dimesylate 10 mg/1 · Tablet, Chewable · Takeda Pharmaceuticals America, Inc.
- 59417-116 Lisdexamfetamine Dimesylate 20 mg/1 · Tablet, Chewable · Takeda Pharmaceuticals America, Inc.
- 59417-118 Lisdexamfetamine Dimesylate 40 mg/1 · Tablet, Chewable · Takeda Pharmaceuticals America, Inc.
- 59417-119 Lisdexamfetamine Dimesylate 50 mg/1 · Tablet, Chewable · Takeda Pharmaceuticals America, Inc.
- 59417-120 Lisdexamfetamine Dimesylate 60 mg/1 · Tablet, Chewable · Takeda Pharmaceuticals America, Inc.
- 59417-101 Lisdexamfetamine Dimesylate 10 mg/1 · Capsule · Takeda Pharmaceuticals America, Inc.
- 59417-102 Lisdexamfetamine Dimesylate 20 mg/1 · Capsule · Takeda Pharmaceuticals America, Inc.
- 59417-103 Lisdexamfetamine Dimesylate 30 mg/1 · Capsule · Takeda Pharmaceuticals America, Inc.
- 59417-104 Lisdexamfetamine Dimesylate 40 mg/1 · Capsule · Takeda Pharmaceuticals America, Inc.
- 59417-105 Lisdexamfetamine Dimesylate 50 mg/1 · Capsule · Takeda Pharmaceuticals America, Inc.
- 59417-106 Lisdexamfetamine Dimesylate 60 mg/1 · Capsule · Takeda Pharmaceuticals America, Inc.
- 59417-107 Lisdexamfetamine Dimesylate 70 mg/1 · Capsule · Takeda Pharmaceuticals America, Inc.